In a combined clinical and genetic institutional study of 510 patients with paediatric low-grade gliomas (PLGGs) [28], BRAF V600E mutation was detected in 69 of 405 patients (17%) and correlated with poor outcomes after chemotherapy and radiation therapy with a 10-year progression-free survival (PFS) of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E-mutated and wild-type PLGG (p < 0.001), respectively. The gene discussed is BRAF; the disease is low grade glioma.